PBS updates

Uvadex (Methoxsalen)

methoxsalen 200 microgram/10 mL injection, 12 x 10 mL vials · EXTRACORPOREAL_CIRCULATION · PBS code 12876Q

STREAMLINED

What it costs

AU$2381.92 PBS-determined price per 12 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

  • • First listed on the PBS: 2022-03-01.
  • • Repeats: 1.
  • • PBS program: HB.
Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic graft versus host disease


Initial treatment in a treatment episode


The condition must be inadequately responsive to systemic corticosteroid treatment at a therapeutic dose, but has never been treated with this drug; or

The condition must have relapsed within 8 weeks of prior PBS-subsidised treatment with this drug administered via extracorporeal photopheresis; or

The condition must have relapsed with each of the following conditions being met: (i) prior PBS-subsidised treatment with this drug administered via extracorporeal photopheresis last occurred at least 8 weeks ago, (ii) a subsequent trial of systemic corticosteroids at therapeutic doses has been completed; AND

Patient must be undergoing treatment with this drug that is being administered within at least one of: (i) the first 12 weeks of a treatment episode, (ii) the first 25 doses (inclusive of the 25th dose) of a treatment episode; AND

Must be treated by a haematologist; or

Must be treated by an oncologist with allogeneic bone marrow transplantation experience; or

Must be treated by a medical practitioner working under the direct supervision of one of the above mentioned specialist types; AND

Patient must be undergoing treatment with this drug following allogeneic haematopoietic stem cell transplantation; AND

Patient must be undergoing concurrent treatment with extracorporeal photopheresis as described in the Medicare Benefits Schedule for this condition.

Sponsor: Terumo BCT Australia Pty Limited ABN 87 130 046 865

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.